LETTER TO THE EDITOR

The 5-HT\textsubscript{4} Agonist Prucalopride Stimulates L-DOPA-Induced Dopamine Release in Restricted Brain Regions of the Hemiparkinsonian Rat \textit{In Vivo}

Sylvia Navailles,\textsuperscript{1} Giuseppe Di Giovanni\textsuperscript{2,3} & Philippe De Deurwaerdère\textsuperscript{1}

\textsuperscript{1} CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
\textsuperscript{2} Neuroscience Division, School of Biosciences, Cardiff University, Cardiff, UK
\textsuperscript{3} Department of Physiology & Biochemistry, Faculty of Medicine and Surgery, University of Malta, Msida, Malta

Correspondence
P. De Deurwaerdère, Université de Bordeaux,
UMR CNRS 5293, Institut des Maladies Neurodégénératives, 146 rue Léo Saignat,
33076 Bordeaux cedex, France.
Tel.: +33-557-574619;
Fax: +33-556-901421;
E-mail: deurwaer@u-bordeaux.fr
Received 14 May 2015; revision 21 June 2015; accepted 22 June 2015
doi: 10.1111/cns.12436

The efficacy of L-3,4-dihydroxyphenylalanine (L-DOPA) in the treatment of Parkinson’s disease (PD) is impaired by anxiety or depression in some patients and iatrogenic side effects such as dyskinesia [1]. Classical pharmacological tools such as selective serotonin reuptake inhibitors could be interesting to limit motor or nonmotor undesirable effects, but they directly target the activity of serotonergic neurons. Indeed, serotonergic (5-HT) neurons are responsible for L-DOPA-induced dopamine (DA) release and some of the inherent behavioral effects at the expense of 5-HT itself [2]. Therefore, the difficulty emerging with the therapies associated with L-DOPA is to enhance central DA tone, without further alteration of 5-HT transmission and excessive striatal DA tone correlated to the possible appearance of dyskinesia [2,3].

Our study makes reference to a recent work published by Men dez-David et al. [4] confirming that 5-HT\textsubscript{4} ligands display interesting and fast onset of anxiolytic and antidepressant action [5]. Part of these effects would be related to their indirect modulatory action of 5-HT neuronal activity where 5-HT\textsubscript{4} receptor stimulation and blockade could enhance and reduce dorsal raphe (DRN) 5-HT neuron activity and release at terminals, respectively [5]. Due to the expression of 5-HT\textsubscript{4} receptors being preserved in the brain of Parkinsonian humans [6], the stimulation and blockade of 5-HT\textsubscript{4} receptors could enhance and reduce the ability of L-DOPA to stimulate the depolarization-dependent outflow of DA from 5-HT neurons, respectively.

We used multisite intracerebral microdialysis in the unilateral 6-hydroxydopamine (6-OHDA) rat model of PD to study the effect of the 5-HT\textsubscript{4} agonist prucalopride or the 5-HT\textsubscript{4} antagonist GR 125487 on the release of DA induced by intraperitoneal (i.p.) 12 mg/kg L-DOPA. Microdialysis probes were simultaneously implanted in the striatum, hippocampus (HIPP), substantia nigra pars reticulata (SNr), and the prefrontal cortex (PFC) [7]. We have chosen a dose for each 5-HT\textsubscript{4} compound that guaranteed selective and efficient action toward 5-HT\textsubscript{4} receptors [8]. The entire experimental procedures were similar to those recently reported [7] and agreed with French National Committee (décret 87/848, Ministère de l’Agriculture et de la Forêt) and European Economic Community (86-6091 EEC) guidelines for the care and use of laboratory animals.

As previously reported [3,7], L-DOPA (12 mg/kg, i.p.) increased DA outflow in the striatum, SNr, PFC, and the HIPP (Figure 1). The 5-HT\textsubscript{4} antagonist GR 125487 (0.1 mg/kg, i.p.) did not modify the effect of L-DOPA suggesting that 5-HT\textsubscript{4} receptors do not contribute to the regulation of the basal activity of 5-HT neurons in the presence of L-DOPA. This is consistent with the fact that L-DOPA tends to decrease 5-HT extracellular levels in the brain [2]. Conversely, 5-HT\textsubscript{4} receptor agonist prucalopride (5 mg/kg, i.p.) selectively enhanced L-DOPA-stimulated DA release in the SNr and the PFC (Figure 1). The use of multisite intracerebral microdialysis allows us to discard peripheral or central pharmacokinetic interaction because the prucalopride-dependent enhancement of L-DOPA-stimulated DA release was not observed in the striatum or the HIPP of the same rats. Consistently, the DA metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) extracellular levels, reflecting circulating L-DOPA, were homogeneously enhanced in all brain regions. The lack of effect of prucalopride on DOPAC extracellular levels further rules out regional changes of L-DOPA availability (data not shown).

The pharmacodynamic interaction might involve the indirect stimulation of 5-HT neurons located in the raphe nuclei and
increase release at terminals, thereby enhancing a depolarization-dependent release of L-DOPA-derived DA at terminals of 5-HT neurons [3]. The selective L-DOPA-stimulated DA release in the SNr and the PFC is likely related in part to the heterogeneous function of 5-HT terminals in the brain [2]. In particular, such depolarization-induced L-DOPA-derived DA outflow might be bypassed in the HIPP. The release of DA induced by L-DOPA may involve an impulse-independent mechanism in the HIPP which might be less present in other brain regions [3]. The role of 5-HT4 receptors in the striatum is unclear. No data have been reported regarding its ability to control the activity of 5-HT terminals in the brain [2]. In particular, such depolarization-induced L-DOPA-derived DA outflow might be bypassed in the HIPP. The release of DA induced by L-DOPA may involve an impulse-independent mechanism in the HIPP which might be less present in other brain regions [3]. The role of 5-HT4 receptors in the striatum is unclear. No data have been reported regarding its ability to control the activity of 5-HT terminals in the brain [2].

Regional changes in 5-HT4 receptor densities or coupling could account for the heterogeneous and regional responses to prucalopride, in particular in the SNr with respect to other brain regions investigated [10].

The main interest here is to report that a 5-HT agonist changes the pattern of L-DOPA-induced DA release. The pattern of L-DOPA-stimulated DA release would be more important than striatal DA release per se in the neurochemical and behavioral outcomes of L-DOPA [3]. A heterogeneous response is, for example, difficult to obtain with blockers of noradrenaline or serotonin transporters which display a widespread expression [3,7]. The increase in DA release in the PFC and the SNr but not in the striatum might correspond to a favorable neurochemical profile. Indeed, the efficacy of L-DOPA cannot be simply related to striatal DA release, while L-DOPA-induced dyskinesia could be consequent to the dramatic loss of DA responses in the SNr and/or PFC compared to the striatum after chronic L-DOPA [3]. Additional studies are warranted to study the effect of 5-HT4 ligands in rats chronically treated with L-DOPA.

5-HT4 agonists, including prucalopride, can already be given in the treatment of constipation to patients with PD [11]. The nonselective 5-HT4 agonist cisapride has been reported to aggravate tremor in PD, although this effect is probably related to other components of its pharmacological profile [9]. The enterokinetic properties of 5-HT4 receptor agonists suggest their potential use against L-DOPA-induced fluctuations in patients with PD [11]. Moreover, 5-HT4 receptor agonists might act as potential antidepressant or anti-Parkinsonian agents in the treatment of PD, although no evaluation has been reported yet in humans. This assumption is based on the work of Mendez-David et al. [4] which recalls that 5-HT4 agonists display anxiolytic/antidepressant properties in the mouse corticosterone model. The 5-HT4 agonist mechanism of action differs from classical 5-HT antidepressant drugs as they indirectly act on the function of 5-HT terminals [5]. In addition, our findings showing favorable neurochemical
pattern of DA release obtained in the presence of L-DOPA, in terms of efficacy without motor side effects [3], would uphold 5-HT₄ agonists as an alternative approach to the treatment of anxiety and/or depression in L-DOPA-treated patients with PD.

Acknowledgments

The project was funded by the Fondation de France and the Centre National de la recherche scientifique. SN received the price of the “Société Française de Physiologie et de Pharmacologie” for this project. PDD and GDG acknowledge the support given by the Cooperation for Science and Technology (COST) action CM1103. The authors thank Dr Jan A. Schuurkes (Movetis, Belgium) for the generous gift of prucalopride.

Conflict of Interest

The authors declare no potential conflict of interest.

References